Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.
Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.
Not yet recruiting · NCT07679269 · Registry updated 2026-09-18Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety. | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Not yet recruiting | Phase 2 | 2026-09-18 | NCT07679269 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Novartis Pharmaceuticals | 432 |
0 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| No products are listed yet. | |||